Syngene Builds Play In 'Exciting' ADCs Space Amid Strong Q2
This article was originally published in Scrip
The newly listed Indian contract research organization (CRO) Syngene International Ltd reported robust second quarter growth, with the top brass also outlining the firm's intent to partake in "exciting" areas such as antibody-drug conjugates (ADCs).
You may also be interested in...
Syngene, one of Asia's largest contract research organizations, has reported strong first quarter numbers and is bolstering its biologics services business with a new viral testing facility. Brexit isn't a "structural event" for Syngene and the CRO's top brass also outlines to Scrip the significant cost advantage that the firm offers over Chinese and Western competitors.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?